HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Maxwellia Adds STI Home-Test To UK Lovi Line

Executive Summary

UK sexual health specialist Maxwellia continues to expand its UK footprint with an STI home-test launch under the Lovi brand umbrella. 

You may also be interested in...



Over The Counter 26 Sept 2023: Disrupting the Consumer Health Industry, With Maxwellia’s Anna Maxwell

In this episode, HBW Insight catches up with UK switch specialists Maxwellia to find out what’s next for the company that gave to the UK one of the first OTC daily contraceptive pills. Now a disruptive consumer health player in its own right, the company is looking for investors to take it to the next level and help launch two new women’s health products in the pipeline for next year, CEO Anna Maxwell reveals in this exclusive interview.

UK's Maxwellia Offers Mid-Price Branded Levonorgestrel Alternative

UK consumers will soon be able to purchase at an "accessible" price branded levonorgestrel-based emergency contraceptive, LoviOne, marketed by switch specialists Maxwellia. 

HRA Pharma And Maxwellia To Launch The UK’s First OTC Daily Contraceptives

The UK's MHRA has approved the Rx-to-OTC switch of two identical progestogen-only contraceptive pills from HRA Pharma and Maxwellia. Hana and Lovima (both 75mcg desogestrel) will be launched at the end of the month. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel